Mercury Bio Welcomes New Finance Director & Closes $2M Early Funding Round
Retrieved on:
Wednesday, August 30, 2023
The seed round, which commenced in January of this year, was swiftly subscribed to by investors from across the nation, both corporations and individuals alike.
Key Points:
- The seed round, which commenced in January of this year, was swiftly subscribed to by investors from across the nation, both corporations and individuals alike.
- Additionally, the company has signified its intent to promptly initiate efforts towards a Series A investment round due to the surge in activity.
- Before January 2023, the company had been funded through pre-seed investments primarily sourced from individuals and organizations based in New Mexico.
- "Mercury Bio really transitioned out of a period of discreet technological development when we unveiled our groundbreaking technology at the recent 3rd-Annual mRNA Therapeutics conference in Boston," says current CEO, Bruce McCormick.